NCT06079736View on ClinicalTrials.gov

A Study Of PGN-EDO51 In Participants With Duchenne Muscular Dystrophy Amenable To Exon 51-Skipping Treatment

PHASE2TerminatedINTERVENTIONAL
Enrollment

7

Participants

Timeline

Start Date

January 8, 2024

Primary Completion Date

August 28, 2025

Study Completion Date

August 28, 2025

Conditions
Duchenne Muscular Dystrophy
Interventions
DRUG

PGN-EDO51

IV infusion

Trial Locations (5)

V6H1G9

British Columbia Children's Hospital, Vancouver

E3B0C7

Stan Cassidy Centre for Rehabilitation, Fredericton

K1H8L1

Children's Hospital of Eastern Ontario (CHEO), Ottawa

M5G0A4

The Hospital for Sick Children (SickKids), Toronto

G1V4G2

CHU de Québec, Québec

Sponsors

Lead Sponsor

PepGen Inc
All Listed Sponsors
lead

PepGen Inc

INDUSTRY